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ABSTRACT: Photoinduced antibacterial gold nanoparticles
were developed as an alternative for the treatment of
antibiotic-resistant bacteria. Thanks to the amoxicillin coating,
they possess high in vivo stability, selectivity for the bacteria wall,
a good renal clearance, and are completely nontoxic for
eukaryotic cells at the bactericidal concentrations. A simple
one-step synthesis of amoxi@AuNP is described at mild
temperatures using the antibiotic as both reducing and stabilizing
agent. Time-resolved fluorescence microscopy proved these
novel nano-photosensitizers, with improved selectivity, are
bactericidal but showing excellent biocompatibility toward
eukaryotic cells at the same dose (1.5 μg/mL) when co-cultures
are analyzed. Their stability in biological media, hemocompat-
ibility, and photo-antibacterial effect against sensitive and
antibiotic-resistant Staphylococcus aureus were evaluated in vitro, whereas toxicity, renal clearance, and biodistribution were
studied in vivo in male Wistar rats. The use of these nanoparticles to treat antibiotic-resistant infections is promising given their
high stability and cytocompatibility.
■ INTRODUCTION
Antibiotic-resistant (AR) bacteria and the lethal infections they
can cause are a subject of public concern.1,2 Indeed, the World
Health Organization has described antibiotic resistance as “a
problem so serious that it threatens the achievements of
modern medicine”.3 Thus, there is an urgent need for the
development of novel strategies and drugs. In recent years,
nanoparticles have been tested as potential antibacterial agents;
particularly, gold nanoparticles (AuNPs) were chosen to act as
photosensitizers because of their inert nature and effectiveness
in spite of their polymorphism and polydispersity.4 Further,
AuNP plasmons can absorb visible light,5 thus avoiding the use
of highly energetic wavelengths that cause cell photodamage,
proving useful for cancer treatment.6 Additionally, we have
shown the photoinduced bactericidal properties of AuNPs
utilizing green light, even on AR clinical strains.7−10 Thus,
plasmon excitation of the AuNPs can produce highly reactive
oxygen species (ROS) levels causing oxidative stress after 4 h of
photodynamic antimicrobial chemotherapy (PACT), leading to
bacterial death. Furthermore, in vitro studies suggest that these
AuNPs are nontoxic for eukaryotic cells. These results
stimulated the present work to explore the selectivity toward
prokaryotic cells in cell co-cultures and the biocompatibility
and distribution of the particles in vivo.
Many in vivo studies on the biodistribution and toxic effects
of AuNPs show that they are controlled by the nanomaterial
size, shape, and coating.11−13 The limited pore size of the
endothelial wall in the tissue is the primary delivery barrier for
nanoparticles, but it also allows selective accumulation in
certain tissues. When nanoparticles are administered through
intraperitoneal (IP) or intravenous injection, a variety of serum
proteins bind to their surface, which are recognized,
internalized, and carried to the liver or spleen.14 It is known
that the majority of the AuNPs after IP injection are distributed
to the liver and spleen in 2−3 h15 and that AuNPs had a high
blood-clearance rate being mostly distributed in the liver,
followed by the spleen and lungs.16 No matter the pathway
used, AuNPs seemed to migrate into the circulatory system first
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and subsequently distributed into tissues and organs, thus
mainly distributed by passive targeting.17
It has been demonstrated that AuNPs can enhance their
bactericidal properties when combined with antibiotics, such as
vancomycin, aminoglycoside, and amoxicillin, among
others.18−23 Amoxicillin is a β-lactam antibiotic24 and, like
other penicillins, binds to and inhibits the carboxypeptidase and
transpeptidase enzymes that are required for peptidoglycan
biosynthesis (Figure S1).25 The nitrogen-containing β-lactam
ring is designed to target the penicillin-binding membrane
proteins, which are involved in the cross-linking of the bacterial
cell wall. Interestingly, amoxicillin is capable of reducing26
Au(III) to Au(0) and stabilizing the resulting AuNPs due to
high affinity of the amino groups to the gold surface.
Here, we present the one-pot synthesis of amoxicillin-coated
AuNPs (amoxi@AuNPs) that combined to show enhanced
photo-antimicrobial effect, i.e., highly reduced amount of
antibiotic (typically 500 mg per dose are used), short irradiation
time (∼30 min), and high selectivity toward prokaryotic cells.
Facile-to-prepare amoxicillin-coated AuNPs were stable inside
the bloodstream and tissue distribution, showing rapid
clearance from the organism at the same time. In this sense,
they are a better option for clinical use in comparison to other
stabilizing agents, such as glutathione.27 Furthermore, we
introduce a novel method to check the selectivity of the toxicity
in a co-culture of bacteria and blood cells through time-resolved
fluorescence microscopy.
■ RESULTS AND DISCUSSION
Synthesis and Characterization of Amoxi@AuNPs.
AuNPs were synthesized by thermal reduction utilizing
amoxicillin as both reducing and stabilizing agent. The
absorption spectrum (Figure 1) of the amoxi@AuNPs shows
the characteristic plasmon band of small spherical nanoparticles
centered around 540 nm, whereas the presence of a second
absorption band around 950 nm can account for the plasmon
absorption bands of more complex nanostructures, namely,
triangular, hexagonal, and irregular polygonal plates, including
nanorods (see Figures S2−S4).28
Dynamic light scattering (DLS) measurements determined a
hydrodynamic radius for the amoxi@AuNPs of 79 ± 43 nm.
The broad distribution of particle sizes found by this technique
is in agreement with the presence of larger nonspherical
nanostructures, in contrast to the AuNPs synthesized with
NaBH4 (“unprotected” AuNPs) that show a more mono-
disperse size distribution: 8 ± 2 nm. The positive ζ (Zeta)
potential value found for amoxi@AuNPs (+30 ± 7 mV)
confirms the effectiveness of the amoxicillin as colloidal
stabilizer.
The conjugation of the stabilizer agent to the nanoparticle
was confirmed by Fourier transform infrared (FT-IR) spec-
troscopy (see Figure S5). AuNPs showed ∼11% amoxicillin
loading, as determined by thermogravimetric analysis (TGA).
This amount is enough to stabilize the particle, but it is very
low compared to the daily dose administered to a patient (1−2
g), which could minimize all of the amoxicillin side effects.29,30
These new amoxi@AuNP composites showed great stability
in different media, such as phosphate-buffered saline (PBS)
37.5, 25, 12.5, and 7.5% for 72 h; ceramide monohexoside
(CMH) 25% for 48 h; CMH 12.5 and 7.5%; CTS 25, 12.5, and
7.5% for 168 h; and Milli-Q water for 96 h. (Figure S6).
Nevertheless, they crashed immediately in all concentrated
biological media and PBS (100 and 50%). On the basis of these
findings, microbiological assays were carried out in 37.5% PBS,
which allows the bacteria to be metabolically active and does
not interfere with the monitoring of the plasmon absorption.
In Vitro Studies. Antibacterial Activity. Staphylococcus
aureus ATCC 29213 (MSSA) and a methicillin-resistant clinical
isolate of S. aureus (MRSA) were killed by 1.5 μg/mL amoxi@
AuNPs after only 30 min of irradiation (Figure 2) with white
light using an light-emitting diode (LED) expo-panel (Figure
S7). This is considerably faster than other nano-photo-
sensitizers we have previously tested under similar exposure
conditions.7,10 It is worth noting that light itself does not
produce any damage or change of the bacterial normal growth.
The selection of white light irradiation was based on the broad
absorption spectrum shown by the amoxi@AuNPs composites
(Figure 1), ensuring the excitation of most of the
nanostructures present in the solution. Interestingly, excitation
using only green light (525 nm) did not produce antibacterial
effect; thus, the bactericidal effect requires the excitation of
more complex nanostructures using the full visible spectrum.
Additionally, amoxi@AuNPs were able to kill all of the MSAA
after 90 min in the dark but not the MRSA. This could be a
consequence of the synergistic effect18,31 between the antibiotic
and the nanoparticle, as amoxicillin alone was not bactericidal at
this low dose. It is important to highlight that the system
temperature was kept at 37−38 °C during all of the
experimental procedures. Despite the constant bulk temper-
ature, it is well known that the excitation of the surface plasmon
of AuNPs can induce a localized heat on the particle surface.
Thus, the high local temperature experienced by the bacteria in
close proximity to the surface of the particle could trigger their
death.32 In fact, gold nanoparticles are able to convert the
absorbed light into heat very efficiently. These results in a hot
lattice and the temperature could increase up to tens of degrees,
enough to denaturalize biomolecules.33−35
ROS Quantification in Bacterial Culture. The generation of
ROS was determined for samples of MRSA phototreated with
amoxi@AuNP (at bactericidal concentrations). Figure 3 shows
the maximum ROS production (almost 25 times basal level)
quantified after just 10 min of irradiation. This level of ROS
generation is even higher than the one observed for S. aureus
treated with AuNP and light.10 A significant amount of ROS
formation (almost 17 times basal level) can be formed after 30
min of irradiation, although no bacterial growth was observed at
Figure 1. Normalized absorption spectra of unprotected AuNP
(black) and of amoxi@AuNPs (red). The absorption wavelength at
around 950 nm accounts for the presence of nonspherical
nanostructures.
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that time. This could be due to the presence of some bacteria
organelles and structures, whose global integrity and function-
ality are too damaged to keep bacteria alive. After 60 min, ROS
production is negligible. Dark levels are almost null (not
shown). The temperature of all of the samples (including the
irradiated ones) was kept at 37 °C during the whole
experiment, avoiding the influence of macroscopic thermal
effect. This significant amount of ROS detected could indicate
that the bactericidal effect is in direct relation with the oxidative
stress generated in bacteria when amoxi@AuNP (attached to
their wall) are irradiated.
Mammalian Cell Viability. The 3T3 cell line has become the
standard fibroblast cell line since Todaro and Green originally
obtained them from Swiss albino mouse embryo tissue in
1962.36,32 This line corresponds to immortalize cells; however,
fibroblasts are much more sensitive to external factors than
HeLa cells, most frequently used for in vitro experiments. For
this reason, the activity of its mitochondrial enzymes, as
evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (MTT) assay, is an important parameter for the
analysis of the effects of new drugs on eukaryotic cells, as it is a
reflection of potential toxicity to mammals. Figure 4 shows the
effect of free amoxicillin, unprotected AuNPs, and amoxi@
AuNPs on their antibacterial or photo-antibacterial concen-
trations. Our results suggest that the cell viability of the samples
Figure 2. Bacterial growth over time of MSSA (A, B) and MRSA (C, D) samples treated under dark conditions (A−C) and under LED illumination
(B−D) in the presence of 1.5 μg/mL of amoxi@AuNPs (red), 0.15 μg/mL amoxi@AuNPs (blue), and as control samples in the presence of
amoxicillin at the minimum inhibitory concentration (MIC, green) or PBS (black). Note that unprotected AuNP at 10× concentration causes
damage to the bacteria after 9−12 h of exposure to light (not shown).10
Figure 3. ROS production for samples of MRSA phototreated with
amoxi@AuNP (at bactericidal concentrations).
Figure 4. Cell survival (%) of fibroblast 3T3 treated with 1.5 μg/mL
amoxi@AuNP, 2 μg/mL unprotected AuNP, 32 μg/mL amoxicillin,
37.5% PBS, and DMEM under 24 h visible light irradiation (red) and
under dark conditions (gray) for 24 h at 37 °C, 5% CO2, and 95%
humidity.
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with antibiotic or nanoparticles is similar to control without
drug (37.5% PBS), and they all presented slightly less survival
than the control with Dulbecco’s modified Eagle’s medium
(DMEM). Free amoxicillin was found to be nontoxic to other
mammal cells in previous literature reports, whereas our own
studies described the biocompatibility of uncoated AuNPs.10,37
Figure 4 shows that amoxi@AuNPs were not cytotoxic even
under the same irradiation conditions used for the antimicrobial
test. Similar results were found for gold nanoparticles
embedded in amphiphilic block copolymers.38 AuNPs are
essentially harmless compared to other antimicrobial nano-
particles, such as zinc nanoparticles, which have a substantial
toxic impact on human fibroblast after 24 h.39 This
demonstrates that the proposed photosensitizer is selectively
toxic for bacteria and does not affect eukaryotic cells to any
significant extent, due to the absence of any penicillin-binding
protein 1A on the eukaryotic membrane.
Parenteral and intraperitoneal injection of nanoparticles can
produce high local concentration and broad distribution in the
circulating blood, leading to the need for evaluation of their
biological safety. Ex vivo experiments on whole blood were
conducted because erythrocytes together with other blood cells
and serum content reflect properly the actual conditions in
mammals.40 Experiments were performed at t = 0, 2, 5, and 24
h in the dark and under LED irradiation, with the bactericidal
concentration of amoxi@AuNP (1.5 μg/mL). Total hemolysis
was established by adding H2O to the red blood cell samples; n
= 3; SD < 0.1 (see Figure S7 for illumination details). The
tested amoxi@AuNPs did not produce any alteration to the red
blood cells, as shown in Table 1. There was no hemolysis at all,
even under irradiation conditions. Thus, the amoxi@AuNPs are
selectively toxic for bacteria and do not affect erythrocytes.
Under these illumination conditions, the photothermal effect is
then harmless for eukaryotic cells.
To further prove that amoxi@AuNPs are selectively toxic for
bacteria, co-cultures with blood cells were treated with the
particles under the same irradiation conditions. The fluo-
rescence lifetime imaging microscopy (FLIM) technique is
extremely useful in bioimaging, where, for instance, light
scattering can interfere with steady-state fluorescence imaging.
The fluorescence lifetime can change depending on the
fluorophore environment and hence the same fluorophore
can be tracked in different locations utilizing the same emission
wavelength. Here, we use this technique together with a well-
known DNA and RNA intercalator, acridine orange (AO-see
Figure S8).41 Concentrations of AO around 0.3 mg/mL (1
mM) or higher lead to the formation of nonfluorescent
dimers.42 However, AO can intercalate in nucleic acid helices as
the cationic monomer can presumably bind through electro-
static interaction with negatively charged phosphate. This
interaction recovers the AO fluorescent properties and is the
reason why AO is extensively used as a biological stain in
fluorescence microscopy. When bound to ssDNA, AO shows a
stable emission maximum at 630 nm upon excitation at around
458 nm. Interestingly, AO, when externally bound to
disorganized or broken genetic material, is energetically less
stable and is also very weakly emissive.43 Here, AO was found
to bind to the genetic material in both live bacteria and cells
showing emission around 630 nm upon excitation at 440 nm.
When the cells are subjected to damage, the genetic material of
a dead cell is severely disrupted if not completely disintegrated.
As a consequence, the AO most likely spreads into the solution
as the nonfluorescent dimer forms or remains externally bound
to the remaining DNA/RNA bases, producing a weak and short
emission. Interestingly, the lifetime of the emissive structures is
different when the AO is attached to live bacteria (ca. 3−7 ns),
live white blood cells (ca. 7−14 ns), or bound externally to the
disrupted genetic material of dying cells (<3 ns) with a lifetime
almost as short as free AO.44 Thus, using time-resolved
fluorescence techniques, we were able to differentiate live
bacteria or eukaryotic cells from dead ones.
According to the lifetime color scale at the bottom of Figure
5, groups of S. aureus appeared bright green when alive (Figure
5A) and the few dead coccus that are dead but were not
completely broken by photothermal effect of PACT appeared
blue (Figure 5B), indicating a decrease in the AO emission
lifetime. Live erythrocytes (without nucleus or genetic material)
were observed as pale green rings (Figure 5C−E) and were not
found after heating the control sample (Figure 5F). The same
sample presented a 98% of hemolysis in parallel measurements.
Regarding eukaryotic cells with genetic material, lymphocytes,
were observed as bright yellow-orange spots when alive (Figure
5C−E) and pale green spots when dying or damaged (Figure
5F). A larger white blood cell (eosinophil) was observed alive
(Figure 5E). Its nucleus appeared dull green because of the lax
chromatin content; however, the AO presented longer
lifetimes, up to 14 ns in the cytoplasm, due its strong
interaction with eosinophilic granules, described by Ueki et al.45
and previously by Robbins et al.46 The aforementioned
difference in the emission lifetime of AO was developed as a
practical and fast method to study the survival of both
eukaryotic and prokaryotic cells together. It requires just one
fluorescent dye, one excitation laser, and one emission filter, in
contrast to other similar techniques that excite AO with
different lasers and need other fluorescent dyes as ethidium
bromide or propidium iodide as contrast agents.47,48
In Vivo Studies. The distribution of the nanoparticles in
internal organs is crucial to determine their in vivo stability and
fate after the desired activity is completed. Following IP
injection (see Experimental Section), amoxi@AuNPs were
found using transmission electron microscopy (TEM) analysis
(Figure 6) inside the liver (rows A and B), the kidney (rows C
and D), and the spleen (rows E and F). Importantly, they did
not go through the brain−blood barrier as amoxi@AuNPs were
not found in brain tissue (data not shown). In general, the
nanoparticles were internalized in vesicles in Kupffer cells in the
liver just 2 h after IP injection. Usually, hepatobiliary system
represents the main route of excretion for particles that do not
undergo renal clearance.49 Nanoparticles of diameter less than
100 nm, smaller than the pore size of liver fenestrae, could have
easily penetrated through the endothelial wall too. At the same
Table 1. Hemolysis Percentage (%) of Blood Samples
Treated with 1.5 μg/mL Amoxi@AuNP and with 0.9% NaCl
as Negative Control and H2O as Positive Control
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time, some amoxi@AuNPs were found in the spleen, indicating
that they had been carried there earlier by the phagocytic cells.
However, for these nanoparticles, our results indicate that the
largest NP amount was found in the kidneys (2 h post
injection) being internalized in vesicles after having gone
through the microvilli. Only a small fraction of the nano-
particles was found in the samples taken 5 h after
administration. This could be due to the elimination in urine
(vide infra) or as a result of normal process of vesicle
degradation because shrunken vesicles were observed (Figure
6IIIC,D). In kidneys and the spleen, where a few nanoparticles
were interacting with the dense chromatin, around 5% of
pyknotic nuclei were observed (n = 1008 cells), possibly as a
consequence of the oxidative stress generated by the nanoma-
terial.50 It is noteworthy that after 24 h all three organs
presented normal histopathology. Their different composing
cells (including hepatocytes, epithelial and endothelial cells,
podocytes, macrophages, and red and white blood cells) looked
unaltered and were of normal size and structure. The AuNP
without antibiotic stabilization were only found in small
quantities in the liver at 2 h, indicating their poor stability in
biological fluids after injection. According to our results, coating
of AuNP is necessary to improve their in vivo stability. To
obtain a global characterization, 2 grids were prepared for each
organ (2 organs for each condition) and over 300 TEM
pictures were taken. The more representative ones were
selected to illustrate the path of the nanoparticles through the
tissues studied (Figure 6).
Additionally, particles larger than the effective pore size in
normal intact endothelium (5 nm), such as those used here,
experience prolonged circulatory times due to slow trans-
portation across the endothelium; therefore, the study of their
effect on blood cells is quite relevant. Cell counting (Table 2)
on samples of rats injected with nanoparticles (groups I and II)
was not different from the control animals (group III), except
for a slight increase in the number of neutrophils (10% over top
reference value, p < 0.05) in group II at 2 h. This is correlated
with the observation of active phagocytic cells in the liver,
kidneys, and spleen at the same time. The elevation in
neutrophils may be due to the host response to the injection
and distribution of amoxi@AuNPs. Normal values were totally
restored after 24 h as a sign of complete elimination of the
nanoparticles from the organism. According to microscope
observation of smears, red blood cells from group I to II kept
their integrity, suggesting that they were not stressed by the
nanomaterial. This finding is in agreement with the ex vivo
hemolysis test results.
Finally, renal excretion is the desirable pathway for AuNP
removal because it would keep the catabolism or breakdown to
a minimum, avoiding possible side effects.49 Renal clearance as
a fundamental part of drug elimination is determined by the
molecular chemical and physical properties, including size,
surface charge, and surface chemistry.51 Without such clearance
or their biodegradation into biologically benign components,
the toxicity potential increases. To address this concern,
qualitative detection of intact nanoparticles in urine was done
by measuring their plasmon absorption (Figure 7). Urine
samples from group II showed an absorption peak (abs < 0.40)
at 540 nm, consistent with spherical AuNP after 5 h of IP
injection. Apparently, other shapes and sizes would preferably
be uptaken by cells and degraded inside vesicles as shown in
TEM pictures. It seems that most of the nanomaterial is being
eliminated between 2 and 5 h after injection because the
plasmon peaks are not bigger in urine samples collected 1 day
after injection than in those collected 5 h after injection; in
agreement with previous report.52 Both works suggest that the
Figure 5. FLIM images of biological samples containing AO: co-culture of MSSA and blood cells treated with amoxi@AuNP for 30 min under dark
conditions (C) and under irradiation (D); S. aureus suspension treated with amoxi@AuNP for 30 min under dark conditions (A) and under
irradiation (B); blood cells treated with amoxi@AuNP for 30 min under dark conditions (E) and heated at 80 °C (F). Color gradient bar at the
bottom indicates lifetime of AO emission in nanoseconds (ns). The scale bar is 20 μm.
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kidneys are the primary sites for clearance of the smallest
particles, followed by the hepatobiliary system. No unprotected
AuNPs were found in urine collected from group I, supporting
the hypothesis that uncoated AuNP are not being well
distributed/eliminated. In summary, amoxicillin is beneficial
not only for the stabilization of the nanoparticles but also for
their renal clearance.
■ CONCLUSIONS
The combination of in vivo and in vitro studies presented here
showed that amoxi@AuNPs are suitable nanostructures for
PACT applications. amoxi@AuNPs can be easily synthesized in
one pot utilizing amoxicillin as both reducing and stabilizing
agent. The particles are stable in biological media and show
Figure 6. Representative TEM images of rat tissue samples showing the biodistribution of amoxi@AuNPs in the liver (rows A and B), kidneys (rows
C and D), and spleen (rows E and F) after intraperitoneal injection. The scale bar is the same (1 μm) for all images.
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photoinduced antibacterial activity (irradiation time ∼30 min),
even against AR strains. Importantly, amoxi@AuNPs are very
biocompatible with eukaryotic cells under PACT conditions.
The bacterial death is believed to occur upon localized surface
plasmon excitation of the AuNP. The antibiotic was used as a
reducing agent for the synthesis of AuNPs, and its presence
confers the NP with the selectivity toward the bacterial cell.
This is a major advantage when combating microorganism that
produce lytic enzymes, developing antibiotic resistance.
Accordingly, the amoxi@AuNPs can act faster than silver and
zinc nanoparticles tested by other groups without plasmon
excitation,53 showing their potential as antibacterial agents.
We have also demonstrated that FLIM can be very useful to
determine the cell selectivity and bactericidal activity in
prokaryotic/eukaryotic co-cultures by a rapid and simple
analysis. This analysis only requires one fluorescent dye, one
excitation laser, and one emission filter, in contrast to similar
techniques that excite AO with different lasers and need other
fluorescent dyes as ethidium bromide or propidium iodide as
contrast agents.
Finally yet importantly, our results show that the injected
AuNPs have a higher clearance rate than other similar
nanomaterials54,55 and have not induced considerable cytotox-
icity responses. As a result, amoxi@AuNPs seem to have a low
potential of accumulation in mammals. These findings are
remarkably useful for the potential development of pharma-
ceutical formulations.
■ EXPERIMENTAL SECTION
Materials. Tetrachloroauric acid-99% (HAuCl4) was
purchased from Sigma-Aldrich, and trihydrate amoxicillin was
purchased from Todo Droga (Argentina). Mueller Hinton
broth (MHB), tryptic soy broth (TSB), tryptic soy agar (TSA),
brain heart infusion, Luria Bertani broth, and phosphate-
buffered saline (PBS) were purchased from Britania (Argenti-
na).
Synthesis of Amoxi@AuNPs and AuNP. Antibiotic-
coated nanoparticles were prepared with amoxicillin in a one-
step synthesis using the antibiotic as both the reducing and
stabilizer agent. This bottom-up method is based on the
reduction of the gold precursor (HAuCl4 100 μL, 10 mM) with
amoxicillin trihydrate (900 μL, 0.1 mM) at 50 °C for 18 min.
This corresponds to a 16 wt % of amoxicillin with respect to the
mass of Au. All solutions were freshly prepared prior to the
synthesis and left to stabilize at room temperature for 30 min
before heating. Three cycles of Milli-Q water washing and
centrifugation were used to remove unbound amoxicillin
molecules.
To obtain 500 mL of 0.2 mM unprotected AuNP, 1 mL of
0.1 M HAuCl4 aqueous solution was added to 500 mL of
previously cooled Milli-Q water (8 °C). Then, 10 mL of a
NaBH4 (0.13 M) solution was transferred dropwise to the flask.
Characterization of Amoxi@AuNP. The changes of the
surface plasmon resonance of the resuspended pellet and the
absorption spectrum of the amoxicillin molecules present in the
supernatant were monitored using a Cary 60 UV−vis
spectrophotometer. The shape and size of the synthesized
AuNPa were measured by transmission electron microscopy
(TEM-Jeol 1200 EX II). Samples for TEM measurements were
prepared by placing a 4 μL drop of the amoxi@AuNP solution
on carbon-coated copper grids and left to dry completely at 37
°C in a drying oven. At least 400 nanoparticles were analyzed
statistically using ImageJ software. On the same samples, ζ
potential and dynamic light scattering (DLS) were measured
with a Malvern Zetasizer (model Nano-S). The binding of
amoxicillin to AuNP was analyzed by a Fourier transform
infrared (FT-IR) spectrometer in transmission mode using a
Nicolet iN 10 spectrophotometer. Samples of amoxicillin
trihydrate, unprotected AuNP, and amoxi@AuNPs were freeze-
dried and then measured by FT-IR at low temperature.
The amount of amoxicillin was determined by thermogravi-
metric analysis (TGA). For this, 4 mL of 1.5 μg/mL of the
amoxi@AuNPs were centrifuged down and pellets were
combined to be exhaustively dried in a desiccator for 48 h
prior to TGA at 10 °C/min from 25 to 1000 °C under nitrogen
atmosphere (flow rate of 25 mL/min) with a TA-THA Q5000.
The TGA curves were used to determine the amoxicillin
amount attached to AuNP by extrapolating the weight loss
values from the y-axis.
Colloidal Stability. Stability measurements of amoxi@
AuNPs (1.5 μg/mL) in different buffer solutions and growth
Table 2. Cell Counting (%) from Blood Smears of Rats Treated with AuNP (I), Amoxi@AuNP (II), and Physicological Saline
Solution (III)
2 h 5 h 24 h
% refa,b I II III I II III I II III
N 1−16 18 26 5 12 16 6 10 11 6
L 82−96 82 74 94 86 82 93 89 87 92
M 0−3 0 0 1 2 2 0 0 2 2
E 0−2 0 0 0 0 0 1 1 0 0
B 0 0 0 0 0 0 0 0 0 0
SN 0−1 0 0 0 0 0 0 0 0 0
a“ref” are the reference values for healthy male Wistar rats. bN (neutrophils), L (lymphocytes), M (monocytes), E (eosinophils), B (basophils), SN
(segmented neutrophils).
Figure 7. Absorption spectra of amoxi@AuNPs from rat urine
collected 5 h (blue) and 24 h (red) after IP injection and resuspended
in 37.5% PBS.
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media were conducted on the basis of the change in plasmon
absorbance maxima at different time points, utilizing UV−vis
spectrophotometry. Stability was considered as the time it took
for a 20% decrease in plasmon absorption at the wavelength of
the initial maximum absorbance.8 The stability measurements
were carried out (using a BioTek plate reader) for 7 days (time
= 0, 0.5, 1, 2, 4, 6, 12 18, 24, 48, 72, 120, 144, 168 h) in Milli-Q
water, saline solution, PBS (pH = 7), Mueller Hinton broth
(MHB), and tryptic soy broth (TSB) at different concen-
trations (100, 50, 25, 12.5%). To avoid contamination, the
stability measurement of nanoparticles dispersed in growth
media was conducted under sterile conditions.
Bacterial Strains and Growth Conditions. The experi-
ments were performed using S. aureus ATCC 29213 (MSSA
ATCC 29213) and a methicillin-resistant clinical isolate of S.
aureus (MRSA 9455). Clinical isolate was supplied by the
Bacteriology Service of Sanatorio Aconcagua, Co ́rdoba,
Argentina. Stock cultures were maintained in TSB and stored
in a freezer in 10% glycerol.
Antibacterial Capacity. Antibacterial activity of novel
amoxi@AuNPs against MSSA and MRSA was tested. Bacterial
suspensions of 106 colony-forming units per milliliter (CFU/
mL) in 37.5% PBS (pH = 7) from a single colony of each strain
were prepared. Using a 96-well plate, 100 μL of bacterial
suspension and 100 μL of the tested solutions (37.5% PBS,
0.15 μg/mL, amoxi@AuNPs, 1.5 μg/mL amoxi@AuNPs, and
amoxicillin at minimum inhibitory concentration (MIC) per
strain as control: 2 μg/mL for MSSA and 32 μg/mL for
MRSA) were mixed and irradiated for a total of 90 min under
white LED illumination at 37 °C. Control experiments were
run under the same conditions in the dark. All samples were
run in triplicate. Aliquots of each sample were diluted properly
and seeded in TSA plates. CFUs were counted from the agar
after 24 h of incubation at 37 °C.
ROS Quantification in Bacterial Culture. The prefluor-
escent probe dihydrorhodamine 123 (DHR) was chosen for its
high sensitivity to quantify total ROS and reactive nitrogen
species.56 This dye diffuses passively through most of cell
membranes, where DHR generates a fluorescent green signal at
536 nm when oxidized. Radical indicators of oxidative stress
were measured with DHR (1 μM) in bacterial suspensions (109
CFU/mL) treated with a 1.5 μg/mL of amoxi@AuNPs. The
samples were irradiated for 10, 30, 60, and 90 min.
Cell Viability. The 3T3 fibroblasts were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) with 10% calf
serum. Cells were grown until 85−95% confluence, then
washed with phosphate-buffer saline (Invitrogen), and trypsi-
nized with 1 mL of 0.05% trypsin, 0.53 mM ethyl-
enediaminetetraacetic acid, phenol red. Trypsinization was
stopped by adding fresh medium to the reaction. The cells were
washed twice by centrifugation with DMEM without serum,
resuspended in medium without serum, and plated at
approximately 105 cells per well after proper cell counting in
an improved Neubauer chamber. They were incubated
overnight to allow attachment and then treated with 1.5 μg/
mL amoxi@AuNP, 32 μg/mL amoxicillin, 37.5% PBS, and
DMEM and irradiated with a white LED for 24 h. The cells
were kept in the dark for 24 h at 37 °C, 5% CO2, and 95%
humidity. MTT assay based on the reduction of tetrazolium salt
to formazan crystals in living cells was done according to a
Sigma protocol to determine the percent survival.57 The
absorbance spectra on the different wells were measured using a
BioTek plate reader.
Hemolysis. The integrity of red blood cells from human
healthy volunteers (from Coŕdoba, Argentina) incubated with
amoxi@AuNPs 1.5 μg/mL with and without irradiation was
evaluated following a procedure previously described58 with
slight modifications. The amoxi@AuNPs had to be removed by
centrifuging the samples before reading the absorbance of the
free hemoglobin (541 nm) to avoid spectral interference.
Measurements were made at 0, 2, 5, and 24 h in triplicate. An
aqueous solution of 0.9% NaCl and H2O were used as negative
and positive controls of hemolysis, respectively.
Fluorescence Lifetime Imaging Microscopy (FLIM)
Study on Co-cultures of Blood Cells and Bacteria.
Acridine orange (AO) was employed due to its characteristic
fluorescence emission when intercalated in DNA or RNA.59,60
FLIM imaging of the dye was introduced as a method to check
the viability of blood cells (anticoagulated fresh samples from
healthy volunteers from University of Coŕdoba) and bacteria
(107 CFU/mL of S. aureus 29213) cultured together and
treated with irradiated and nonirradiated amoxi@AuNPs (1.5
μg/mL). The samples were studied using a fluorescent lifetime
imaging system (FLIM, PicoQuant MicroTime 200). The
instrument was equipped with a frequency-doubled picosecond
pulse diode laser (440 ± 10 nm, 70 ps, 40 MHz, LDH-D-C-
440, PicoQuant). The laser beam was collimated and focused
through a fiber-coupling unit. A beam splitter Z440 bcm
(Chroma) was used to reflect the excitation light into the oil
immersion total internal reflection objective (100×, NA1.45,
Olympus, PLAPO). The excitation dose (average power) is
about 0.6 mW for all samples. Emission was collected between
610 and 680 nm using the ET645/75BP emission filter. Briefly,
100 μL of the biological sample and 100 μL of AO (1 mg/mL)
were mixed and incubated at room temperature for 5 min.
Lifetimes longer than 5 ns were found for live bacteria and cells,
whereas dead bacteria or cells can be detected by a decrease in
the emission intensity and lifetime of unbound AO produced
by disorganization of the spread genetic material in necrotic or
broken cells. Aliquots of the dye alone or mixed with amoxi@
AuNPs were also tested for fluorescence. Fresh samples of
blood cells or PBS suspension of bacteria in the absence of
nanoparticles were run as controls for “alive samples”.
Accordingly, the same samples were also heated up to 80 °C
and imaged as “dead samples control”. Furthermore, bacterial
growth in the observed samples was also ruled out by CFU
counting in MH agar plates, whereas integrity of eukaryotic
cells was monitored by parallel hemolysis measures.
Biodistribution of Nanoparticles. Male Wistar rats with a
body weight of 280−310 g at the time of drug administration
were maintained in the animal house facility at the
Departamento Farmacologiá, Coŕdoba, Argentina (food and
water provided ad libitum at a constant temperature of 22 ± 2
°C with 12 h by 12 h light and dark cycle). The rats were
handled for 1 week for acclimatization. At the beginning, the
rats were divided into three groups of two rats each: group I
was subjected to intraperitoneal injection with 34 μg/mL
AuNP, group II with 1.5 μg/mL amoxi@AuNPs, and group III
with physiological saline solution as control. After 2, 5, and 24 h
post injection, two animals from each group were anesthetized
using a mixture of 55 mg/kg ketamine and 11 mg/kg xylazine.
Immediately, cardiac perfusion with PBS (0.1 M) was carried
out to remove all red blood cells from their internal organs.
Finally, after proper fixation (35 min perfusion with 2%
paraformaldehyde and 2% glutaraldehyde in PBS), the liver,
heart, kidney, spleen, and brain were harvested. TEM images
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were taken with a TEM-Zeiss-Leo 906E microscope. All
experiments on animals were conducted complying the
ARRIVE guidelines and were carried out in accordance with
the National Institutes of Health Guide for the Care and Use of
Laboratory Animals (NIH Publications No. 8023, revised
1978) and the Guide for the Care and Use of Laboratory
Animals (Eighth Edition, 2011).61
Biocompatibility with Blood Cells. Prior to perfusion,
blood smears (triplicates) were made from fresh blood
extracted through a cardiac puncture.62 Samples were stained
with May Grunwald/Giemsa and analyzed under an optical
microscope. Results reported are the averages of quadruplicates.
Student t-test was performed to detect differences that were
considered statistically significant when P values were lower
than α = 0.05.
Renal Clearance. At the same time intervals (2, 5, and 24
h), urine was collected using metabolic boxes. The plasmon
absorption of the AuNP was measured by spectroscopy using a
multiwell spectrophotometer (BioTek), by centrifuging the
collected urine and resuspending the pellet in 0.5 mL of 37.5%
PBS.
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